vvDD-hIL-2-RG-1

vvDD-hIL-2-RG-1 is a recombinant **oncolytic vaccinia virus (VV)** engineered for cancer immunotherapy. The backbone, known as **vvDD**, features deletions in both the thymidine kinase (TK) gene and the viral growth factor (VGF) gene, which enhances tumor selectivity and safety compared to standard strains[1][3]. This construct is further armed with the **human interleukin-2 (hIL-2) gene**, allowing localized expression of hIL-2 in tumor tissues, thereby stimulating local immune activation[3][10]. The RG-1 suffix likely refers to a specific design or variant including a rigid linker and cell anchoring, maximizing immune activation in the tumor microenvironment[3]. Preclinical and early clinical data suggest vvDD-hIL-2-RG-1 can efficiently infect, replicate in, and lyse cancer cells, and produce hIL-2 to recruit and activate immune cells in the tumor, enhancing antitumor immunity[3][10]. The primary indication is metastatic gastrointestinal and peritoneal tumors, with ongoing phase 1 clinical evaluation as an intratumoral therapy[4][5][7][10].

Other names

Vaccinia virus double-deleted human interleukin 2